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Mineralocorticoid receptor (MR) antagonists are known to have beneficial effects in patients with cardiovascular
disease without renal failure. However, there have been few published studies on the effectiveness of MR
antagonists in dialysis patients, and most of the studies were small-sized. The present review focuses on the
effectiveness of MR antagonists and the risk of hyperkalemia in dialysis patients. Severe hyperkalemia due to
treatment with MR antagonists in dialysis patients is not common, particularly in peritoneal dialysis (PD) patients,
and the prospect of cardioprotective effects has been hopeful in both hemodialysis (HD) and PD patients. Further
studies are required to establish optimal protocols for the use of MR antagonists in these patients without adverse
effects.
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The number of patients with end-stage renal disease
(ESRD) who are undergoing dialysis is increasing. Al-
though dialysis treatment techniques have improved,
cardiovascular mortality in dialysis patients is still 10 to
20 times higher than in the general population [1]. In
addition, data from the Japanese Society of Dialysis at
the end of 2013 showed that heart failure constituted
26.8% of the main causes of death in dialysis patients in
Japan [2]. Mineralocorticoid receptor (MR) antagonists
have been reported to improve the prognosis of chronic
heart failure [3, 4], heart failure after acute myocardial
infarction [5], and left ventricular (LV) hypertrophy [6]
among patients without renal failure. In contrast in the
patients with advanced renal failure, MR antagonists
have not been recommended because of concern of
causing hyperkalemia [7, 8]. This review article summa-
rizes the beneficial effects of MR antagonists for patients
with cardiovascular disease as discussed in recent re-
ports, and evaluates the efficacy of treatment with MR
antagonists and risk of hyperkalemia in patients receiv-
ing hemodialysis (HD) and peritoneal dialysis (PD).* Correspondence: yasuito@med.nagoya-u.ac.jp
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Since 1960 spironolactone has been used as a
potassium-sparing diuretic to control edema, hyperten-
sion, ascites of cirrhosis, and primary aldosteronism by
inhibiting the mineralocorticoid (aldosterone) receptor
[9]. Aldosterone acts on epithelial cells such as renal col-
lecting duct tubules and intestinal mucosa, and controls
the extracellular fluid volume by increasing sodium re-
absorption [10–12]. Because aldosterone is located in
the most downstream area of the renin-angiotensin-
aldosterone system, it has been thought to indirectly
cause cardiovascular disorders through the increase of
extracellular fluid volume and hypertension [13]. In large
cohort studies, MR antagonists showed reduction of
mortality in the patients with severe heart failure and
acute myocardial infarction complicated by left ventricu-
lar dysfunction. These effects were suggested not to be
related to hemodynamic effects. [3, 5]. Patients with pri-
mary aldosteronism are known to have a higher inci-
dence of LV hypertrophy, stroke, and microalbuminuria
than patients with essential hypertension. In addition,
the occurrence rate of LV hypertrophy is higher in pa-
tients with primary aldosteronism than in patients with
other types of secondary hypertension [14]. These re-
ports suggest that aldosterone can cause direct organ
damage independent of blood pressure.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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gans such as the brain, heart, and blood vessels; and the
MR produces a variety of actions in each organ (Table 1)
[15–17]. The effects of aldosterone on the cardiovascular
system have been widely reported in relation to vascular
remodeling [18, 19], endothelial dysfunction [20, 21], in-
creased oxidative stress [22], vascular inflammation pro-
motion [23], and cardiomyocyte hypertrophy [24], either
by aldosterone alone or through cooperative action with
angiotensin II or salt intake [25, 26].
In the heart, aldosterone has been reported to play a
role in inducing cardiac hypertrophy. In particular, al-
dosterone with salt-loading induces cardiac hypertrophy
associated with fibrosis, which is attenuated by MR
blockade [24, 27]. Aldosterone and high salt administra-
tion for 4 weeks was observed to induce upregulation
for nuclear factor (NF)-κB, nicotinamide adenine di-
nucleotide phosphate oxidase (NADPH oxidase), and
oxidative stress, leading to increases in monocyte
chemoattractant protein-1 (MCP-1), intracellular adhe-
sion molecule 1 (ICAM1), tumor necrosis factor alpha
(TNF-α), and macrophage infiltration in the perivascular
area of the intramyocardial coronary arteries and at sites
of myocardial injury [22].
The MR, which is expressed not only in the endothe-
lial cells but also in the vascular smooth muscle cells
[28], has been reported to be involved in vascular injury.
For vascular endothelial cells, aldosterone and the MR
are related to endothelial dysfunction, coagulation, in-
flammation and fibrosis, nitric oxide (NO) synthesis, andTable 1 Effects of aldosterone in associated disorders [25]
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PAI-1 plasminogen activator inhibitor-1oxidative stress [29]. Endothelial dysfunction is one of
the factors of atherosclerosis. Aldosterone exacerbates
neointimal thickening after balloon injury and is blocked
by spironolactone [30]. Aldosterone has been reported
to induce a prothrombotic condition by upregulation of
plasminogen activator inhibitor-1 [31]. Aldosterone was
also shown to induce inflammation through upregulation
of oxidative stress, which was ameliorated by spironolac-
tone [32]. Aldosterone was found to downregulate NO
production in vascular endothelial cells, resulting in inhib-
ition of vascular relaxation, which was attenuated with
MR blockade [33, 34]. Interestingly, in vivo studies in rab-
bits with high cholesterol diets showed that eplerenone re-
duced superoxide generation and improved endothelial
function [35]. Also, in monkeys receiving high cholesterol
diets, eplerenone improved endothelium-dependent relax-
ation [36]. In the recent report, MR in endothelial cells
was shown to play a role in regulating endothelial function
in hypertension using the mice with MR specifically de-
leted in the endothelial cells [37].
In vascular smooth muscle cells, aldosterone induced
proliferation [38] and oxidative stress [39]. Aldosterone
activated the mitogen-activated protein (MAP) kinases
and NADPH oxidase through c-Src, leading to damage
of vascular smooth muscle cells [39]. In addition, spir-
onolactone inhibited the progression of aortic calcifica-
tion in rats with adenine-induced chronic kidney disease
(CKD) because of suppression of osteogenic transition
and apoptosis in the aorta [40]. Recently, arterial stiff-
ness was shown to be modulated by MR activation in
vascular smooth muscle cells using a mouse with condi-
tional inactivation of MR in these cells [41]. The main
functions of aldosterone are summarized in Table 1.
Effects of the MR antagonists in hemodialysis patients
There have been many reports about the cardioprotec-
tive effects of MR antagonists and the concomitant risk
of hyperkalemia in HD patients (Table 2).
Risk of hyperkalemia
In a 1983 study, spironolactone at 300 mg/day was ad-
ministered to 9 HD patients for 3 weeks. At the end of
the study, plasma potassium levels were significantly in-
creased [42]. However, the patients in this study had re-
ceived a higher dose of spironolactone than that used
commonly. Saudan et al. [43] reported 14 HD patients
who received low-dose spironolactone at 12.5 mg × 3/
week after dialysis sessions for 2 weeks. Then, the dose
was increased to 25 mg × 3/week and continued for
2 weeks in comparison with 21 HD control patients.
The serum potassium levels did not significantly differ
between the two groups (4.9 ± 0.7 in the spironolactone
group and 4.9 ± 0.3 mEq/l in the control group). Hussain
et al. [44] reported that 15 HD patients with serum
Table 2 Effects of MR antagonists in hemodialysis patients
Author Number of patients Administration period Study duration Results Change of plasma potassium
Papadimitriou et al. [42] 9 HD patients Spironolactone 300 mg/day 3 weeks Blood pressure remained unchanged. Plasma potassium levels increased.
Saudan et al. [43] 14 HD patients Spironolactone 12.5 mg ×
3/week for 2 weeks; then
increased 25 mg × 3/week
for 2 weeks
4 weeks Serum potassium levels did not
differ between spironolactone
group and control group (4.9 ± 0.7
vs. 4.9 ± 0.3 mEq/l, N.S.).
Hussain et al. [44] 15 HD patients Spironolactone 25 mg/day 28 days 4.6 ± 0.6 at baseline 4.9 ± 0.9 mEq/l
at study completion (P = 0.14).
One patient developed hyperkalemia
(K = 7.6 mEq/l).
Nitta et al. [55] 5 HD patients Spironolactone 50 mg/day 3.1 ± 1.2 years ACI decreased.
Plasma osteopontin decreased.
Gross et al. [45] 8 HD patients Spironolactone 50 mg × 2/day 2 weeks Systolic blood pressure reduced.
Plasma aldosterone and renin activity
were not significantly different from
placebo group.
Spironolactone group 5.0 ± 0.8 versus
placebo group 4.7 ± 0.5 mEq/l (P > 0.05).
Taheri et al. [48] 8 HD patients with
heart failure and
LVEF ≤45%
Spironolactone 25 mg × 3/week 6 months LVEF and LV mass improved. Potassium level increased by 21% in
the spironolactone group.
McGill et al. [49] 13 HD patients Spironolactone 25 mg/day 9 months Cardiac MRI was not improved.. There was no incidence of hyperkalemia
(K > 6.0 mEq/l).
Matsumoto et al. [53] 61 HD patients Spironolactone 25 mg/day 6 months Potassium levels were 4.96 ± 0.72 at
baseline and 5.18 ± 0.72 mEq/l at 6
months (P < 0.05). No patients
developed over 6.8 mEq/l.
Vukusich et al. [56] 33 HD patients Spironolactone 50 mg × 3/week 2 years CIMT decreased. No patients developed hyperkalemia,
but the potassium levels in the
spironolactone group increased
(P < 0.001).
Shavit et al. [46] 8 HD patients Eplerenone 25 mg × 2/day 4 weeks Systolic blood pressure reduced. Plasma potassium concentration was
4.67 ± 0.2 at baseline and 4.86 ± 0.38
mEq/l after 4 weeks (P = 0.48).
Flevari et al. [50] 14 HD patients Spironolactone 25 mg × 3/week 4 months Blood pressure controlled, the reactive
hyperemia and heart rate variability
improved. LV dimensions and mass
were not improved.
The potassium level increased from
4.4 ± 0.2 to 5.5 ± 0.3 mEq/l (P < 0.05).
Two patients took cation exchange
resin due to hyperkalemia (K > 6 mEq/l).
Matsumoto et al. [52] 157 HD patients Spironolactone 25 mg/day 3 years Death or hospitalization for CCV
events and all-cause mortality reduced.
Potassium level was 5.16 at baseline vs.
5.14 mEq/l after 3 years. Three patients
discontinued in spironolactone because
of hyperkalemia.
Walsh et al. [47] 77 HD patients Eplerenone 50 mg/day 13 weeks Discontinuation of the drug because
of hyperkalemia or hypotension was
not different.
Nine patients developed hyperkalemia
(K > 6.5 mEq/l) in the eplerenone group













Table 2 Effects of MR antagonists in hemodialysis patients (Continued)
Feniman-De-Stefano et al. [51] 8 HD patients Spironolactone 25 mg/day 6 months LV mass index decreased. There was no significant difference
between spironolactone and placebo
groups (5.0 ± 0.31 in the spironolactone
group vs 4.9 ± 0.24 mEq/l in the control
group, P = 0.568).
Lin et al. [54] 125 HD + PD patients Spironolactone 25 mg/day 2 years CCV events and the rates of death
from all causes reduced. LV mass
index, LVEF, and FMD were improved.
Potassium level rose from 4.12 ± 0.42 to
5.32 ± 0.68 mEq/l after 2 years, but was
not significantly elevated compared with
the control group (P = 0.13).
ACI aortic calcification index, CCV cardiovascular and cerebrovascular, CIMT carotid intima-media thickness, EF ejection fraction, ESRD end-stage renal disease, FMD flow-mediated dilation, HD hemodialysis, LV left ven-
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lactone at 25 mg/day for 28 days. The mean potassium
levels did not significantly increase (before - 4.6 ±
0.6 mEq/l; after - 4.9 ± 0.9 mEq/l, P = 0.14); however, the
potassium level of one patient rose to 7.6 mEq/l, and
this patient was dropped from the study. Gross et al.
[45] reported a randomized, double-blinded, placebo-
controlled study in which 8 HD patients were adminis-
tered spironolactone 50 mg × 2/day or placebo for
2 weeks; after a 3-week washout period, the patients
crossed over in the treatment arms for 2 more weeks.
After administration of spironolactone for 2 weeks,
systolic blood pressure was significantly reduced from
142.0 ± 19.6 to 131.4 ± 18.2 mmHg (P < 0.05). In
contrast, plasma potassium levels were not different
between spironolactone treatment and placebo groups
(5.0 ± 0.8 vs 4.7 ± 0.5 mEq/l, P = n.s.). Similar trials were
reported using eplerenone, another MR antagonist.
Shavit et al. [46] treated 8 HD patients with low-dose
eplerenone at 25 mg × 2/day for 4 weeks. After 4 weeks,
the systolic blood pressure was reduced from 166 ± 14 to
153 ± 10 mmHg (P < 0.05); however, there was no signifi-
cant change in the potassium level (before - 4.67 ±
0.2 mEq/l, after - 4.86 ± 0.38 mEq/l, P = 0.48). In
addition, Walsh et al. [47] conducted a randomized,
double-blinded, placebo-controlled study of 154 HD pa-
tients. In the study, 77 and 77 patients were treated with
eplerenone 50 mg/day or placebo, respectively, and
followed for 13 weeks. Nine patients developed hyperka-
lemia (K > 6.5 mEq/l) in the eplerenone group compared
with two patients in the placebo group (relative risk, 4.5;
95% confidence interval, CI 1.0–20.2); however, there
was no significant difference in the dropout rate from
adverse events (hyperkalemia or hypotension) between
the two groups.
Effects on cardiovascular disease
The effects of MR blockade on cardiac function in HD
patients have also been reported. First, Taheri et al. [48]
conducted a randomized, double-blinded, placebo-
controlled study in 16 HD patients with heart failure
and low LV ejection fraction (EF) ≤45%, who received
spironolactone at 25 mg × 3/week (n = 8) or placebo (n
= 8). After 6 months, the mean EF significantly increased
in the spironolactone group compared with the placebo
group (6.2 ± 1.64 vs. 0.83 ± 4.9%, P = 0.046), and the
mean LV mass decreased in the spironolactone group
compared with the placebo group (-8.4 ± 4.72 vs. 3 ±
7.97%, P = 0.021). The potassium level increased by 21%
in the spironolactone group, but the incidence of hyper-
kalemia was not significantly increased. McGill et al.
[49] conducted a small-sized study of 13 HD patients
treated with spironolactone at 25 mg/day for 9 months
and evaluated LV mass by cardiac magnetic resonanceimaging. No improvements in LV mass were detected.
Another research group reported a small-sized study
with 14 HD patients without heart failure who received
low-dose spironolactone at 25 mg × 3/week. After
4 months, blood pressure control, reactive hyperemia,
and heart rate variability were significantly improved,
while LV dimensions or mass were not improved [50].
Feniman-De-Stefano et al. [51] conducted a small-sized
randomized, double-blinded, placebo-controlled study in
which 17 HD patients were divided into 2 groups. Eight
HD patients received spironolactone and 9 patients re-
ceived placebo for 6 months; the spironolactone was ad-
ministered at 12.5 mg/day for 1 week, after which the
dose was increased to 25 mg/day. The LV mass index
was significantly reduced from 77 ± 14.6 g/m2.7 to 69 ±
10.5 g/m2.7 (P = 0.039) in the spironolactone group,
whereas in the placebo group there was an increase from
71 ± 14.2 to 74 ± 17.4 g/m2.7 (P > 0.05).
Matsumoto et al. [52] conducted a large-scale random-
ized trial in HD patients. These investigators performed
a pilot study to evaluate the safety of spironolactone.
Sixty-one HD patients received spironolactone at 25 mg/
day for 6 months. The mean potassium level was signifi-
cantly higher at the end of the study than at baseline,
but no patients developed a potassium level >6.8 mEq/l
[53]. Based on the safety of this pilot study, Matsumoto
et al. [52] conducted a 3-year follow-up randomized
trial. One hundred fifty-seven HD patients who received
spironolactone at 25 mg/day were compared with 152
control patients. The composite rate of death or
hospitalization due to cardiovascular and cerebrovascu-
lar (CCV) events during 3 years was 5.7% in the spirono-
lactone group and 12.5% in the control group. Death
from all causes was 6.4% in the spironolactone group
and 19.7% in the control group. The average potassium
level did not increase significantly; however, 3 patients in
the spironolactone group discontinued the study because
of developing hyperkalemia during the study. Lin et al.
[54] also reported a multicenter, randomized, placebo-
controlled study in which 125 HD + PD patients received
spironolactone at 25 mg/day and 128 patients received
placebo for 2 years. Death from CCV events occurred in
4.0% of the spironolactone group vs 11.7% in the control
group. All-cause mortality was 9.6% in the spironolactone
group and 19.5% in the control group. LV mass index,
LVEF, and flow-mediated dilation were significantly im-
proved from baseline in the spironolactone group but not
in the control group. The potassium level rose from 4.12
± 0.42 to 5.32 ± 0.68 mEq/l but was not significantly ele-
vated compared with the control group. Three patients in
the spironolactone group experienced an increase in their
plasma potassium levels up to 6.0~6.5 mEq/l.
The effects of spironolactone on blood vessels have
also been reported. Nitta et al. [55] reported a small
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for 3.1 ± 1.2 years and were evaluated for the aortic cal-
cification index (ACI) by abdominal computed tomog-
raphy scan. The mean ACI was significantly decreased
from 27.0 ± 12.8 to 18.6 ± 11.8% (P = 0.003). Vukusich
et al. [56] performed a randomized, double-blinded,
placebo-controlled trial in 33 HD patients who received
spironolactone at 50 mg × 3/week and in 33 HD control
patients. After 2 years, carotid intima-media thickness
significantly improved in the spironolactone group com-
pared with the placebo group.
Taken together, hyperkalemia does not commonly
occur in HD patients who receive treatment with MR
antagonists; however, attention should be paid to serum
potassium levels. Cardioprotective effects have been
shown in many reports. Two reports described an im-
provement in mortality [52, 54]; therefore, MR antagonists
hold promise for improving the prognosis in HD patients.
Effects of MR antagonists in peritoneal dialysis patients
Cardioprotective effects and risk of hyperkalemia in
peritoneal dialysis patients
The number of reports on MR antagonists with respect to
their cardioprotective effects and adverse effects in PD pa-
tients, summarized in Table 3, has been fewer than the
number of reports in HD patients. In 2002, Hausmann
et al. [57] first reported a 73-year-old patient on PD who
received spironolactone at 25 mg/day, in whom the EFTable 3 Effects of MR antagonists in peritoneal dialysis patients






One PD patient Spironolactone
25 mg/day
10 months






Ito et al. [60] 78 PD patients Spironolactone
25 mg/day
2 years










9 PD patients Spironolactone
25 mg/day
6 months
CA125 cancer antigen 125, EF ejection fraction, GFR glomerular filtration rate, LV leftimproved from 32 to 46% after 10 months. Taheri et al.
[58] conducted a small-sized randomized, double-blinded,
placebo-controlled study in which 18 PD patients with
heart failure received spironolactone at 25 mg (n = 9) or
placebo (n = 9) every other day for 6 months. The EF in
the placebo group did not change (before - 33.3 ± 11.7 vs
after - 34.2 ± 11.6, P = 0.363); however, the EF in the spir-
onolactone group significantly improved (before - 25.7 ±
7.3 vs after - 33.3 ± 7.8, P = 0.002). Although there was no
significant difference in the serum potassium level be-
tween the spironolactone and placebo groups, one patient
in the spironolactone group developed hyperkalemia with
K = 5.70 mEq/l. After the Taheri study, Yongsiri et al. [59]
reported a small-sized, randomized, double-blinded,
placebo-controlled, crossover study that focused on
changes in potassium levels. Twenty-four PD patients
with hypokalemia received spironolactone at 25 mg/day
for 4 weeks. The serum potassium levels did not change
significantly (4.23 ± 0.64 vs 3.90 ± 0.59 mEq/l in the pa-
tients who received spironolactone, P = 0.077), but one pa-
tient in the spironolactone group developed hyperkalemia
with K = 5.6 mEq/l.
Because most of the studies on the effects of spirono-
lactone in dialysis patients have been small-sized, we
conducted a multicenter, open-label, prospective, ran-
domized trial to investigate the add-on effects of MR an-
tagonists in PD patients [60]. One hundred fifty-eight
PD patients treated with an angiotensin-convertingResults Change of plasma potassium
LVEF increased. Potassium level was below 5.1 at pretreatment
and below 5.5 mEq/l after spironolactone
treatment.
LVEF increased. There was no significantly difference between
spironolactone and placebo groups (P > 0.05).
One patient in the spironolactone group
developed hyperkalemia (K = 5.70 mEq/l).
LV mass index and
LVEF improved.
Potassium levels were significantly higher in the
spironolactone group after 6 and 12 months
(P < 0.05).
Two patients in the spironolactone group
developed hyperkalemia (K = 6.0 mEq/l), and
one patient (K = 6.1 mEq/l) in the control group.
Potassium levels 4.23 ± 0.64 at base line and
3.90 ± 0.59 mEq/l after 4 weeks (P = 0.077). One
patient in the spironolactone group developed





Potassium level 4.3 ± 0.5 at baseline and 4.4 ±
0.6 mEq/l after 6 months (P = 0.488).
CD20 and collagen
IV levels in peritoneal
biopsy specimens
decreased.
Potassium levels 4.8 ± 0.4 in the spironolactone
group and 4.4 ± 0.5 mEq/l in the control group
(P = 0.2).
ventricular, MR mineralocorticoid receptor, PD peritoneal dialysis
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onist were enrolled from 12 hospitals in the Tokai area in
Japan. Seventy-eight PD patients received spironolactone
at 25 mg/day for 2 years, and 80 patients as the control
group did not receive spironolactone. The rate of change
in the LV mass index and LVEF in the spironolactone
group improved significantly compared with the control
group (LV mass index - P = 0.01, EF - P = 0.02). In the
present study, the effects of spironolactone were clearly
shown in the males, whereas we could not show useful-
ness in the females because an insufficient number of
females was enrolled. Serum potassium levels were signifi-
cantly elevated in the spironolactone group at 6 months
and 12 months after treatment with spironolactone. Only
two patients in the spironolactone group developed hyper-
kalemia (maximum K level 6.0 mEq/l); on the other hand,
one patient in the control group developed hyperkalemia
(K level 6.2 mEq/l). There was no significant difference in
the occurrence of hyperkalemia between the two groups
(P = 0.62). Moreover, hypokalemia (potassium level <
3.0 mEq/l) occurred in 25% of the control group and
15.4% of the spironolactone group [60].
Protective effects on the peritoneal membrane in PD
patients
Peritoneal membrane deterioration associated with peri-
toneal fibrosis and neoangiogenesis is one of the import-
ant problems for patients receiving long-term PD [61].
Peritoneal injury is caused by bioincompatible peritoneal
dialysis solution [62–64], peritonitis [65–67], and uremia
[68, 69]. MR antagonists have been reported to amelior-
ate peritoneal fibrosis in a rat peritonitis model [70, 71].
Two reports have discussed the effects of spironolac-
tone on the peritoneal membrane in PD patients. Yelken
et al. [72] reported 23 PD patients who received spirono-
lactone at 25 mg/day for 6 months. After spironolactone
administration, mean dialysate cancer antigen 125 sig-
nificantly increased (P = 0.028), while the potassium
level did not change significantly (4.3 ± 0.5 at baseline
vs 4.4 ± 0.6 mEq/l after 6 months, P = 0.488).
Vazquez-Rangel et al. [73] conducted a randomized,
double-blinded, placebo-controlled study. Nine PD pa-
tients received spironolactone at 25 mg/day for
6 months and underwent peritoneal biopsies when
the PD catheter was placed and at the conclusion of
follow-up. Spironolactone decreased the CD20 and
collagen IV levels in the peritoneal biopsy specimens
in the patients who received spironolactone compared
with the placebo group. There was no significant dif-
ference in the potassium level between the 2 groups.
The effects of MR antagonists on the peritoneal
membrane in PD are still obscure. Future studies are
necessary to determine whether MR blockade is use-
ful for ameliorating peritoneal damage in PD patients.These reports indicate that the risk of severe hyperka-
lemia is not significantly increased in patients receiving
MR treatment, and the cardioprotective effects produced
by MR antagonists are promising in PD patients.
Conclusions
Recent evidence has suggested that administration of
low-dose MR antagonists does not significantly elevate
the risk of hyperkalemia, and that cardioprotective ef-
fectiveness is provided by MR antagonists in both HD
and PD patients. Moreover, MR antagonists are expected
to improve mortality in ESRD dialysis patients. Since
most of the studies have been small size and used short
observation periods, further large-scale clinical studies
are required to establish the protocol for use of MR an-
tagonists in dialysis patients.
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